Tuesday, October 21, 2014 Last update: 6:33 PM
FreshNews.com - Covering Large & Obscure Tech Companies Since 1996

Acceleron Pharma to Present at Upcoming Investor Conferences in September

Companies mentioned in this article: Acceleron Pharma

CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that over the next two weeks, it will participate in several investor conferences.

     

Event:

FBR Inaugural Healthcare Conference

Date / Time:

Wednesday, September 3, 2014

Location:

Four Seasons Hotel, Boston, Mass.

 

Event:

Citi 9th Annual Biotech Conference

Date / Time:

Wednesday, September 3, 2014 at 2:00 PM (EDT)

Location:

Mandarin Oriental Hotel, Boston, Mass.

 

Event:

JMP Securities Boston Biotechnology Day

Date / Time:

Friday, September 5, 2014 at 9:30 AM (EDT)

Location:

The Langham Hotel, Boston, Mass.

 

Event:

Morgan Stanley Global Healthcare Conference 2014

Date / Time:

Tuesday, September 9, 2014 at 8:00 AM (EDT)

Location:

Grand Hyatt New York Hotel, New York, N.Y.

 

A live audio webcast of the presentation at the Morgan Stanley conference will be available on the “Events and Presentations” page in the Investors & Media section on the Company’s website (http://investor.acceleronpharma.com/events.cfm).

A replay of the webcast will also be available from Acceleron’s website.

About Acceleron

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta (TGF-β) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated innovative clinical and preclinical protein therapeutic candidates with novel mechanisms of action. These protein therapeutic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases.

For more information, please visit www.acceleronpharma.com.


Copyright © Business Wire 2014
Contact:

Acceleron Pharma Inc.
Kevin F. McLaughlin, 617-649-9204
Senior Vice President and Chief Financial Officer
or
Media:
Suda Communications LLC
Maureen L. Suda, 585-387-9248